Compare Mesoblast Limited (MESO) vs Nutrien Ltd (NTR) Price & Performance

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Nutrien (NTR) trades at $66.43, up 0.18% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating revenue expectations, driven by higher potash prices. Financials show a net income margin of 8.44% for 2025, with a P/E ratio of 13.62 indicating reasonable valuation. Recent news highlights institutional buying and dividend declarations, while cash flow trends indicate consistent operational strength amid net outflows.

Outlook remains cautiously optimistic with a consensus price target of $76.17, suggesting 14.6% upside, supported by analyst buy ratings at 60.6%. Key opportunities include structural gas arbitrage benefits and agricultural cycle recovery, but risks involve input cost pressures, volatile fertilizer demand, and earnings consistency challenges. The stock presents a value opportunity with dividend yield, though macroeconomic and sector-specific headwinds warrant monitoring.